Evidence map›Paper›PMID 37036544›Full record

ArticleHealth & justice2023

Implementation of rapid COVID-19 testing at Massachusetts trial courts.

Yvane Ngassa, Emma Smyth, Bridget Pickard, Morgan Maner, Lauren Brinkley Rubinstein, Alysse Wurcel

Open access · goldAbstract read
In one paragraph

Article in Health & justice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yvane NgassaDepartment of Medicine, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, 15 Kneeland St, Boston, MA, 02111, USA. yvane.ngassa@tuftsmedicine.org.ORCID http://orcid.org/0000-0002-5188-8762
Emma SmythDepartment of Medicine, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, 15 Kneeland St, Boston, MA, 02111, USA.
Bridget PickardDepartment of Medicine, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, 15 Kneeland St, Boston, MA, 02111, USA.
Morgan ManerBrody School of Medicine, Eastern Carolina University, Greenville, NC, USA.
Lauren Brinkley RubinsteinDepartment of Population Health Sciences, Duke University, Durham, NC, USA.
Alysse WurcelDepartment of Medicine, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, 15 Kneeland St, Boston, MA, 02111, USA.
Tufts Medical Center · USDuke University · US

Funding

National Institute for Health Care Management Foundation 3UG-DA050072NIEHS NIH HHS K08HS026008-01A
6 · The paper itself

Abstract

backgroundCOVID-19 shut down trial courts across the country, prolonging case resolution of charged, detained, and incarcerated people. We report on the implementation of rapid COVID-19 testing at Trial Courts in Massachusetts (MA), focusing on the outcomes of adoption and acceptability.

methodsGuided by the Expert Recommendations in Implementing Change (ERIC) framework, we chose six strategies to guide implementation. After assembling a group of stakeholders, including representatives of the Trial Court, Department of Public Health (DPH) and vendors providing COVID-19 testing, we implemented rapid COVID-19 testing at Trial Court locations in December 2021. We collected data on (1) adoption of COVID-19 testing, (2) number of stakeholders who attended meetings, (3) number of tests performed at Trial Court sites, and (4) acceptability of COVID-19 testing using a QR-code anonymous survey.

resultsThere was a high percentage of attendance at stakeholder meetings (> 70% at each meeting). 243 COVID-19 tests were conducted on eight occasions at four Trial Court sites between December 2021 and February 2022. Participants who responded to the QR-code survey reflected favorably on COVID-19 testing at MA Trial Court sites.

conclusionCOVID-19 testing at Massachusetts Trial Court sites was possible through stakeholder engagement. Several cases of COVID-19 were identified prior to entry into the Trial Court. Funding for rapid COVID-19 testing should be provided to help keep trial courts open as the pandemic continues to evolve.

Indexed as

COVID-19 testingCriminal-legalJustice-involvedTrial court

Identifiers

PMID37036544
PMCPMC10084651
OpenAlexW4363646207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.